ARTICLE | Finance

Aduro's bolus of new investors

How Aduro plans to use $51.4M D round to expand cancer immunotherapy program

January 12, 2015 8:00 AM UTC

Aduro BioTech Inc. cashed in on an eventful 2014 by adding $51.4 million that Chairman, President and CEO Stephen Isaacs said gives the cancer immunotherapy company the ability to expand clinical activities "well into 2017."

The cash came in an untranched series D round last week from new investors that included OrbiMed, Janus Capital Management, Franklin Advisers, Jennison Associates, Foresite Capital Management and Clough Capital Partners...